Global disease experts say little is known about China's experience with long-term COVID effects thought to have afflicted millions with debilitating fatigue, brain fog and other symptoms
Britain approves Pfizer's antiviral COVID-19 pill
Britain has approved Pfizer's COVID-19 pill for patients over the age of 18 years who have mild to moderate infection and are at high risk of their illness worsening.
Published : 31 Dec 2021, 12:22 PM
Updated : 31 Dec 2021, 12:22 PM
The approval comes as the country scrambles to build its defences amid a record hit a daily record of new COVID-19 cases on Thursday, government data showed surge in COVID-19 cases.
Based on data, the pill, Paxlovid, is most effective when taken during the early stages of COVID-19, Britain's Medicines and Healthcare products Regulatory Agency (MHRA) said on Friday, recommending that the drug be used within five days of the onset of symptoms.
Pfizer this month said Paxlovid showed near 90% efficacy in preventing hospitalisations and deaths in high-risk patients, and recent lab data suggests the drug retains its effectiveness against the fast spreading Omicron variant of the coronavirus.
"We now have a further antiviral medicine for the treatment of COVID-19 that can be taken by mouth rather than administered intravenously. This means it can be administered outside a hospital setting," MHRA chief June Raine said in a statement.
RELATED STORIES
The demonstrations helped to end COVID restrictions but failed to achieve lasting political change, six participants based in China and overseas say
The agency seeks details on an increase in respiratory illnesses and reported clusters of pneumonia in children, which its China office called a ‘routine’ check
The inquiry is examining the government's response to the coronavirus pandemic that shut large sections of the economy and killed more than 220,000 people in Britain
